DUBLIN, April 07, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Nordics Seasonal Influenza Vaccination Market Forecast" report to their offering.
According to this report, Sweden is having the highest seasonal influenza vaccine market share.
In terms of children vaccination, Sweden & Denmark hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 60 percent market share by 2022.
This report provides a complete analysis of 5 Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) Seasonal Influenza Vaccine Market for Childhood & Adolescent, Number of Vaccinated Population for Childhood & Adolescent and Forecast till 2022.
Market Dynamics
Seasonal Influenza Vaccine - Growth Drivers
- Vaccine Manufacturers Plan to Increase Flu Vaccine Production
- Growing Child & Ageing Population in Nordic Region
- Rising Healthcare Expenditure Share of the Nordic Countries GDP
Seasonal Influenza Vaccine - Challenges
- Regulatory Challenges with New and Novel Influenza Vaccines
- Lack of Healthcare Infrastructure
- Limited Reimbursement and Access to the Vaccines
All the 5 countries in the report have been studied from 2 viewpoints:
1. Seasonal Influenza Vaccine Market in Nordic Countries (2011 - 2022)
- Seasonal Influenza Vaccine Market & Forecast
- Children Seasonal Influenza Vaccine Market & Forecast
- Adult Seasonal Influenza Vaccine Market & Forecast
2. Seasonal Influenza Vaccinated Population in Nordic Countries (2011 - 2022)
- Seasonal Influenza Vaccinated Population & Forecast
- Children Seasonal Influenza Vaccinated Population & Forecast
- Adult Seasonal Influenza Vaccinated Population & Forecast
Key Topics Covered:
1. Executive Summary
2. Nordic Countries Seasonal Influenza Vaccinated Population
3. Nordic Countries Seasonal Influenza Vaccine Market
4. Nordic Countries Seasonal Influenza Vaccine Market Share Analysis
5. Denmark
6. Finland
7. Iceland
8. Norway
9. Sweden
10. Seasonal Influenza Vaccine - Growth Drivers
11. Seasonal Influenza Vaccine - Challenges
For more information about this report visit http://www.researchandmarkets.com/research/8nm52h/nordics_seasonal
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article